Skip to main content
SpringerLink
Log in

Expression of CD47 antigen in Reed–Sternberg cells as a new potential biomarker for classical Hodgkin lymphoma

  • Brief Research Article
  • Published:
Clinical and Translational Oncology Aims and scope Submit manuscript

Abstract

Introduction

CD47 over expression has been reported in several tumor subtypes. CD47 interacts with SIRPalpha on macrophages inhibiting phagocytic signal, providing a survival advantage to tumor. CD47, therefore, represents a valuable target for immunotherapy and is currently under clinical investigation. We aimed to study CD47 expression in Hodgkin Reed Sternberg cells (HRS).

Methods

We tested a polyclonal CD47 antibody (LifeSpan Biosciences, Seattle, WA) expression along with classical HRS cell markers on a tissue array of 16 classical Hodgkin Lymphoma (CHL) tumor biopsies obtained from newly diagnosed, non-selected patients (8 Female, 8 Male patients) in our institution from October 2016 to January 2018. Histologic subtypes were nodular sclerosis in 11 cases, mixed Cellularity in 3 cases and lymphocyte rich in 2 additional cases. Median age was 53 years (Range: 8, 74). Early stage disease was found in three patients without unfavorable prognostic factors according to EORTC and GHSG criteria, one patient with unfavorable prognostic factors and nine patients had advanced disease. Bulk disease was present in one patient. Normal lymphoid tissue and normal prostate epithelium were used as normal controls as recommended by manufacturer. Approval from the Local Ethical committee was obtained before any analysis.

Results

CD47 was overexpressed on all HRS cells with a characteristic dot-like pattern in 13/13 cases of CHL. HRS clearly expressed CD47 more intensely than infiltrating T and stromal cells.

Discussion

We propose that HRS cells, by up-regulating CD47, might avoid innate immunity check on tumor growth, which could be circumvented using blocking monoclonal antibodies.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2

Similar content being viewed by others

References

  1. Brown EJ, Frazier WA. Integrin-associated protein (CD47) and its ligands. Trends Cell Biol. 2001;11(3):130–5.

    Article  CAS  Google Scholar 

  2. Matozaki T, Murata Y, Okazawa H, Ohnishi H. Functions and molecular mechanisms of the CD47-SIRPalpha signalling pathway. Trends Cell Biol. 2009;19(2):72–80.

    Article  CAS  Google Scholar 

  3. Zhao XW, van Beek EM, Schornagel K, et al. CD47-signal regulatory protein-α (SIRPα) interactions form a barrier for antibody-mediated tumor cell destruction. Proc Natl Acad Sci USA. 2011;108(45):18342–7.

    Article  CAS  Google Scholar 

  4. Chao MP, Weissman IL, Majeti R. The CD47-SIRPα pathway in cancer immune evasion and potential therapeutic implications. Curr Opin Immunol. 2012;24(2):225–32.

    Article  CAS  Google Scholar 

  5. Liu X, Kwon H, Li Z, Fu YX. Is the CD47 an innate immune checkpoint for tumor evasión? J Hematolo Oncol. 2017;10(1):12.

    Article  Google Scholar 

  6. Pardoll DM. The blockade of immune checkpoints in cancer immunotherapy. Nat Rev Cancer. 2012;12(4):252–64.

    Article  CAS  Google Scholar 

  7. Willingham SB, Volkmer JP, Gentles AJ, et al. The CD47-signal regulatory protein alpha (SIRPa) interaction is a therapeutic target for human solid tumors. Proc Natl Acad Sci USA. 2012;109(17):6662–7.

    Article  CAS  Google Scholar 

  8. Liu X, Pu Y, Cron K, et al. CD47 blockade triggers T cell-mediated destruction of immunogenic tumors. Nat Med. 2015;21(10):1209–15.

    Article  CAS  Google Scholar 

  9. Vonderheide RH. CD47 blockade as another ckeckpoint therapy for cancer. Nat Med. 2015;21(10):1122–3.

    Article  CAS  Google Scholar 

  10. Majeti R, Chao MP, Alizadeh AA, et al. CD47 is an adverse prognostic factor and therapeutic antibody target on human acute myeloid leukemia stem cells. Cell. 2009;138(2):286–99. https://doi.org/10.1016/j.cell.2009.05.045

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  11. Chao MP, Alizadeh AA, Tang C, et al. Anti-CD47 antibody synergizes with rituximab to promote phagocytosis and eradicate non-Hodgkin lymphoma. Cell. 2010;142(5):699–707.

    Article  CAS  Google Scholar 

  12. Lian S, Xie R, Ye Y, Lu Y, Cheng Y, Xie X, Li S, Jia L. Dual blockage of both PD-L1 and CD47 enhances immunotherapy against circulating tumor cells. Sci Rep. 2019;9:4532.

    Article  Google Scholar 

Download references

Funding

This research was funded by Mutual Médica (Grant No. Trabajo financiado con el premio de accésit a la Beca Mutual Médica del año 2016).

Author information

Authors and Affiliations

  1. Department of Hematology, Alvarez Buylla Hospital, Mieres, Asturias, Spain

    B. López-Pereira

  2. Department of Pathology, University Hospital Central de Asturias, Oviedo, Asturias, Spain

    A. A. Fernández-Velasco, I. Fernández-Vega & D. Corte-Torres

  3. Department of Hematology, University Hospital Central de Asturias, Oviedo, Asturias, Spain

    C. Quirós, P. Palomo, S. González, A. P. González, Á. Payer, T. Bernal, S. Alonso-Álvarez & E. Colado

  4. Department of Laboratory Medicine, University Hospital Central de Asturias, Oviedo, Asturias, Spain

    C. Quirós, M. A. Moro-García, R. Alonso-Arias, S. Alonso-Álvarez & E. Colado

  5. Department of Pediatrics, University Hospital Central de Asturias, Oviedo, Asturias, Spain

    J. A. Villegas

  6. Department of Immunology, University Hospital Central de Asturias, Oviedo, Asturias, Spain

    R. Alonso-Arias

Authors
  1. B. López-Pereira
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. A. A. Fernández-Velasco
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. I. Fernández-Vega
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. D. Corte-Torres
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. C. Quirós
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. J. A. Villegas
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. P. Palomo
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. S. González
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. A. P. González
    View author publications

    You can also search for this author in PubMed Google Scholar

  10. Á. Payer
    View author publications

    You can also search for this author in PubMed Google Scholar

  11. T. Bernal
    View author publications

    You can also search for this author in PubMed Google Scholar

  12. M. A. Moro-García
    View author publications

    You can also search for this author in PubMed Google Scholar

  13. R. Alonso-Arias
    View author publications

    You can also search for this author in PubMed Google Scholar

  14. S. Alonso-Álvarez
    View author publications

    You can also search for this author in PubMed Google Scholar

  15. E. Colado
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to E. Colado.

Ethics declarations

Conflict of interest

The authors declare that they have no conflict of interest.

Ethical approval

The study was approved by the local Ethical Committee of the Central University Hospital of Asturias. All patients enrolled provided written informed consent.

Informed consent

All patients enrolled provided written informed consent.

Additional information

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Electronic supplementary material

Below is the link to the electronic supplementary material.

Supplementary file1 (DOCX 222 kb)

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

López-Pereira, B., Fernández-Velasco, A.A., Fernández-Vega, I. et al. Expression of CD47 antigen in Reed–Sternberg cells as a new potential biomarker for classical Hodgkin lymphoma. Clin Transl Oncol 22, 782–785 (2020). https://doi.org/10.1007/s12094-019-02171-2

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s12094-019-02171-2

Keywords

Search

Navigation